
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NM-101
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Single Ascending Dose Study
Details : NM-101 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 18, 2025
Lead Product(s) : NM-101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NM-101
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NM-101 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 30, 2023
Lead Product(s) : NM-101
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tomaralimab
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Bioasis
Deal Size : Undisclosed
Deal Type : Collaboration
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
Details : Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 10, 2022
Lead Product(s) : Tomaralimab
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Bioasis
Deal Size : Undisclosed
Deal Type : Collaboration
